CEO Amit Kumar purchases 21,000 shares of ANIX at $2.50; sixth buy at ticker with 5 of 5 prior ANIX trades well-timed at 90-day mark.
Amit Kumar, CEO of Anixa Biosciences, purchased 21,000 shares at $2.50 on 2026-06-12, increasing his holdings to 630.8K shares (+3.4% from 609.8K). This marks his sixth open-market purchase at this ticker. His prior five ANIX trades each demonstrated positive 90-day returns (ranging from +8.4% to +56.2%), and all five were well-timed entries. However, the current price of $2.48 sits -54.6% from the 52-week high, and the stock has declined -12.1% over the past 30 days and -14.2% over 90 days. Against this backdrop of recent weakness and unprofitable fundamentals ($-2.5M net income in the latest period), the consistency of his prior ANIX timing pattern (5 of 5 well-timed at 90 days) provides context for investor evaluation of this purchase's significance.
ANIX CEO buys 5,000 shares at $3.16; 2 peers also bought in past 14 days; stock -22.9% from 52-week high.
CEO Amit Kumar purchased 5,000 shares at $3.16 on 2025-07-30, expanding his stake to 579.9K shares. This buy occurred within a cluster pattern—two other insiders also purchased ANIX shares within the preceding 14 days—suggesting coordinated accumulation at depressed valuations. At his prior ANIX trades, Kumar achieved 90-day returns of +27.8%, +39.4%, and -15.5% respectively, with 2 of 3 prior purchases well-timed at the 90-day mark, indicating consistent success identifying entry points at this ticker. The current price of $3.06 sits -22.9% from the 52-week high of $3.97, and the company remains unprofitable with $-2.8M net income on quarterly revenue of $210.0K, making fundamental recovery a prerequisite for shareholder gains.
ANIX CEO Kumar Amit bought 5,000 shares at $3.15; stock -19.4% from 52-week high, company unprofitable with $-2.8M net income last year.
Amit purchased 5,000 shares at $3.15, adding to 574.9K shares held post-transaction, at a time when Anixa Biosciences is trading -19.4% from its 52-week high of $3.97 and the stock is down 4.2% over the prior 30 days. The company remains unprofitable with $-2.8M net income over its most recent full fiscal year and minimal revenue of $210.0K last quarter, signaling structural headwinds. Across his prior 4 ANIX trades, Amit's timing outcome is mixed: 2 of 3 measurable 90-day intervals were well-timed (buys on 2025-01-15 and 2024-06-07 saw subsequent gains of +27.8% and +39.4% respectively), but his trade on 2024-03-15 resulted in a -15.5% 90-day decline, indicating inconsistent accuracy in identifying recovery points even at this specific ticker. The current purchase into a depressed price within 90 days of his prior June 4 buy carries moderate insider credibility from his favorable historical returns, but the company's persistent unprofitability and zero annual revenue growth warrant scrutiny of whether this represents conviction or routine portfolio activity.
ANIX CEO buys 10,000 shares at $2.85; holdings now 569,925 shares. Stock -28.5% from 52-week high but +8.0% in 30 days.
CEO Amit Kumar purchased 10,000 shares of Anixa Biosciences on 2025-06-04 at $2.85, expanding his holdings to 569,925 shares (+1.8%). His prior two purchases at ANIX showed divergent timing outcomes: the January 2025 buy delivered 90-day gains of +27.8%, while the March 2024 buy resulted in 90-day losses of -15.5%, indicating inconsistent predictive value of his buy decisions at this ticker. The company is unprofitable with $-2.8M net income on quarterly revenue of $210.0K, and zero annual revenue growth, creating a speculative risk profile. Stock is currently $2.84, down -28.5% from the 52-week high of $3.97, though it has recovered +8.0% over the prior 30 days, leaving the timing and motivations of this purchase open to interpretation given the fundamental challenges and uneven pattern of his prior ANIX trades.
CEO Amit Kumar bought 43,000 ANIX shares at $2.23 on 2025-01-15; stock down 54.6% from 52-week high and unprofitable company.
CEO Amit Kumar purchased 43,000 shares at $2.23, increasing his holdings from 516,925 to 559,925 shares, during a period when ANIX has declined 54.6% from its 52-week high of $5.02. The purchase is modest in scale (+8.3% to his holdings) and occurs at a price $0.05 below the current $2.28 market price. Anixa is unprofitable with quarterly revenue of only $210,000 and full-year net income of -$3,277,000, with zero annual revenue growth. His prior two purchases at this ticker delivered mixed results: the June 2024 buy saw a 90-day return of +39.4%, while the March 2024 buy showed a 90-day return of -15.5%, indicating inconsistent outcomes at this specific holding. The open-market purchase during a sustained price decline and amid the company's weak financial fundamentals merits investor scrutiny of the underlying thesis.
